Physician
Shareef Pediatrics, PLLC
Shareef Pediatrics, PLLC was paid $9.45M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
33Billing provider infoSHAREEF PEDIATRICS, PLLC
EDINBURG, TX 78539
EDINBURG, TX 78539
33aNPI1225498231assigned 03/03/2016
33bProvider typePediatrics Physician
28Total paid$9.45M
24GClaims394,000
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#27 of 1,136
Median peer was paid$329K
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 125 | $5K | |
| 2019 | 110 | $4K | |
| 2020 | 7,761 | $176K | |
| 2021 | 65,939 | $1.49M | |
| 2022 | 101,934 | $2.33M | |
| 2023 | 107,990 | $2.63M | |
| 2024incomplete | 110,141 | $2.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 70,682 | 44,318 | $2.56M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 12% | 31,131 | 26,733 | $1.18M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9.1% | 11,396 | 11,057 | $856K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.9% | 50,448 | 22,323 | $655K |
| S8301 | Infection control supplies, not otherwise specified | 5.8% | 35,833 | 24,898 | $551K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.2% | 6,613 | 6,111 | $490K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.4% | 5,176 | 5,085 | $414K |
| G0315 | Immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 5-15 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt) | 4.1% | 13,842 | 12,952 | $389K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.9% | 28,196 | 24,782 | $371K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.3% | 29,463 | 11,289 | $315K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.9% | 5,417 | 5,164 | $270K |
| 99429 | 2.7% | 8,543 | 8,387 | $260K |
66 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.1% | 2,490 | $197K |
| 99203 | Doctor's office visit, new patient (routine) | 1.7% | 2,720 | $157K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.1% | 14,205 | $103K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,158 | $93K |
| 87634 | <1% | 1,559 | $88K | |
| 99381 | <1% | 940 | $75K | |
| 99382 | <1% | 711 | $65K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,884 | $49K |
| 99383 | <1% | 539 | $49K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,368 | $47K |
| 87807 | <1% | 3,410 | $35K | |
| 90461 | <1% | 8,084 | $27K | |
| 92567 | <1% | 1,934 | $24K | |
| 83655 | <1% | 2,097 | $20K | |
| 99050 | <1% | 1,669 | $17K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,252 | $16K |
| 99051 | <1% | 11,192 | $12K | |
| 99000 | <1% | 1,230 | $10K | |
| 99384 | <1% | 88 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 183 | $8K |
| 99463 | <1% | 66 | $7K | |
| 99460 | <1% | 66 | $5K | |
| 0071A | <1% | 132 | $5K | |
| 96380 | <1% | 262 | $5K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 62 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 125 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,775 | $3K |
| 0072A | <1% | 59 | $2K | |
| 0081A | <1% | 51 | $2K | |
| 96160 | <1% | 1,178 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,124 | $942.76 |
| 0082A | <1% | 12 | $480.00 | |
| 90686 | <1% | 3,510 | $437.09 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 27 | $276.99 |
| 92551 | <1% | 221 | $196.61 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $194.48 |
| 86580 | <1% | 15 | $107.73 | |
| 90656 | <1% | 425 | $17.48 | |
| 85018 | <1% | 12 | $12.04 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15 | $3.78 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 27 | $2.37 |
| 90651 | <1% | 389 | $0.01 | |
| 90670 | 0% | 2,855 | $0.00 | |
| 90648 | 0% | 4,374 | $0.00 | |
| 90700 | 0% | 1,107 | $0.00 | |
| 90707 | 0% | 1,169 | $0.00 | |
| 90710 | 0% | 889 | $0.00 | |
| 90734 | 0% | 130 | $0.00 | |
| 90633 | 0% | 2,396 | $0.00 | |
| 91308 | 0% | 76 | $0.00 | |
| 90671 | 0% | 1,745 | $0.00 | |
| 90380 | 0% | 184 | $0.00 | |
| 99173 | 0% | 236 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 536 | $0.00 |
| 90715 | 0% | 47 | $0.00 | |
| 90681 | 0% | 33 | $0.00 | |
| 90381 | 0% | 91 | $0.00 | |
| 90680 | 0% | 3,298 | $0.00 | |
| 90620 | 0% | 27 | $0.00 | |
| 90716 | 0% | 1,161 | $0.00 | |
| 90696 | 0% | 815 | $0.00 | |
| 90723 | 0% | 3,163 | $0.00 | |
| 90698 | 0% | 309 | $0.00 | |
| 91307 | 0% | 222 | $0.00 | |
| 90660 | 0% | 101 | $0.00 | |
| 90744 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHAREEF, RIAZ (PRESIDENT)